Debunking the Bottleneck Myth - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Debunking the Bottleneck Myth
A look at the true cost-drivers of cell-culture production.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 86-87

In the first scenario, a company operating Phase III clinical-trial manufacturing at full scale (10,000–15,000 L bioreactors or larger) does not keep its process scale small or sufficient enough to make only the amount of product they require for the study. The quantities of raw materials and consumables to be purchased at scale, as a result, constitute a significant cost to the company's research and development (R&D) budget. Worse, resins and other consumables cannot be used for their full lifetime.

In the second scenario, a company producing small quantities (as much as a few hundred kilograms) in the same size bioreactors as the first company faces the same issue. Very few batches are run, and the resins are not used for their full lifetime. Pricing of consumables, however, follows the economic value of the products where lifetime is a significant factor. In large facilities, things can get quite expensive in this case.

Will these factors lead to the end of the dinosaurs in biopharmaceutical manufacturing? Or will they serve as the beginning of a single-use age?

Most forecasters agree that very few new antibodies will require large, ton-scale production, or even more than a few hundred kilograms. Product titers at 5 g/L will allow companies to manufacture annual quantities in bioreactors as small as 500 L, certainly in 1000 L. This scale isssue cannot be ignored much longer. Companies will need to adopt the entire scale-up strategy, including the planning of clinical manufacturing. Facilities of the future could be built with a few different bioreactor sizes, none larger than 2000 L. Most future facility models may also include disposable equipment, assuming the equipment can play an important role after a thorough cost-benefit analysis is completed for potential use. In some cases, the benefits of disposables are small or nonexistent; individual case studies are necessary. There is also a scale limitation to consider when thinking about using disposables.

Regardless of the presence of disposables, most important in new facility designs will be the responsiveness of the facility to changing demands and its ability to accommodate new products at different scales while addressing cost concerns.

The real paradigm shift will happen when companies move new production away from the dinosaur bioreactor farms and leave it to the first-generation legacy processes that industry has agreed may be suboptimal but "best to keep." Technical bottleneck issues and related cost concerns would disappear momentarily.

This true "paradigm shift" would represent a fundamental change in manufacturing strategy. This article is not trying to talk industry into keeping the status quo. Rather, it's about looking for improvements in the right places and following the good old 80:20 rule, in which you solve 80% of the problem first and thereby gain 80% of the benefit. Relevant cost reductions are not likely to be found in alternative technologies alone. Suboptimal, inherited facilities and process designs, as well as overdimensioning of production, are today's true cost drivers.

Günter Jagschies, PhD, is a senior director of strategic customer relations at GE Healthcare Life Science Biotechnologies R&D, Björkgatan 30 S-75184, Uppsala, Sweden, tel. +46 18 6120880, fax +46 18 6121863,


1. B. Kelley, "Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations," Biotechnol. Prog., 23, 995–1008 (2007).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here